PTP-MEG2 Inhibitors via Segmented Binding Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective and potent inhibitors for protein tyrosine phosphatases (PTPs), particularly PTP-MEG2, is challenging due to the highly conserved active site, which makes it difficult to design inhibitors that target specific members of the PTP enzyme family effectively.
Innovation Solution
Synthesis of novel PTP inhibitor compounds starting from phosphonodifluoromethyl phenylalanine (F2Pmp) to create selective inhibitors that target both the active site and adjacent peripheral binding pockets, such as compound 7, which is a potent and selective inhibitor of PTP-MEG2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If active site-directed inhibitors are designed to target PTPs, then inhibition potency can be achieved, but selectivity is lost due to the highly conserved active site across PTP family members
Solution Approach 1:
The inhibitor is divided into two functional segments: a pTyr mimetic core that binds to the conserved active site (ensuring potency) and a peripheral recognition motif that binds to variable peripheral pockets (ensuring selectivity). This segmentation allows each part to fulfill its specific binding function independently.
Solution Approach 2:
Different regions of the inhibitor are designed with distinct binding characteristics: the core region targets the conserved active site for high-affinity binding, while the peripheral region targets variable pockets for specificity. This local differentiation of binding properties resolves the contradiction between potency and selectivity.
2Adaptability or versatility
If inhibitors are designed to target only the conserved active site, then broad PTP inhibition is achieved, but specificity for individual PTP members is lost
Solution Approach 1:
The inhibitor architecture separates the broad-spectrum binding function (pTyr mimetic core) from the specificity-determining function (peripheral recognition motif), allowing each segment to optimize its respective role without compromise.
Solution Approach 2:
The design extends binding interactions from the traditional single active site dimension to include both the active site and peripheral pockets, creating a two-dimensional binding surface that simultaneously achieves broad inhibition and member-specificity.
Data Source
AI summary
Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided.